Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells

Published on Sep 27, 2019in International Journal of Molecular Sciences4.183
· DOI :10.3390/ijms20194800
Hanna Maja Tunset2
Estimated H-index: 2
Astrid Jullumstrø Feuerherm8
Estimated H-index: 8
+ 2 AuthorsSiver Andreas Moestue14
Estimated H-index: 14
Metastatic disease is the leading cause of death in breast cancer patients. Disrupting the cancer cell’s ability to migrate may be a strategy for hindering metastasis. Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer. In this study, we aim to characterize the response to reduced cPLA2α activity in metastatic versus non-metastatic cells. We employ an isogenic murine cell line pair displaying metastatic (4T1) and non-metastatic (67NR) phenotype to investigate the role of cPLA2α on migration. Furthermore, we elucidate the effect of reduced cPLA2α activity on global gene expression in the metastatic cell line. Enzyme inhibition is achieved by using a competitive pharmacological inhibitor, cPLA2α inhibitor X (CIX). Our data show that 4T1 expresses significantly higher cPLA2α levels as compared to 67NR, and the two cell lines show different sensitivity to the CIX treatment with regards to metabolism and proliferation. Inhibition of cPLA2α at nontoxic concentrations attenuates migration of highly metastatic 4T1 cells, but not non-metastatic 67NR cells. Gene expression analysis indicates that processes such as interferon type I (IFN-I) signaling and cell cycle regulation are key processes regulated by cPLA2a in metastatic 4T1 cells, supporting the findings from the biological assays. This study demonstrates that two isogenic cancer cell lines with different metastatic potential respond differently to reduced cPLA2α activity. In conclusion, we argue that cPLA2α is a potential therapeutic target in cancer and that enzyme inhibition may inhibit metastasis through an anti-migratory mechanism, possibly involving Toll-like receptor signaling and type I interferons.
  • References (58)
  • Citations (1)
📖 Papers frequently viewed together
9 Authors (Hui Fu, ..., Hua Guo)
16 Citations
22 Citations
151 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Chaelin Lee (Sejong University)H-Index: 1
#2Hien Thi Thu Do (Sejong University)H-Index: 1
Last. Inmoo Rhee (Sejong University)H-Index: 2
view all 6 authors...
Abstract Inflammasomes are the major mechanistic complexes that include members of the NOD-like receptor (NLRs) or AIM2-like receptors (ALRs) families, which are affiliated with the innate immune system. Once NLRs or ALRs are activated by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), the caspase-1 or -11 is activated by binding with NLRs or ALRs via its own unique cytosolic domains. As a result, caspase-1 or -11 enhances the production of IL-1β a...
2 CitationsSource
#1Zahra Zandi (Tehran University of Medical Sciences)H-Index: 1
#2Bahareh Kashani (Tehran University of Medical Sciences)H-Index: 1
Last. Seyed H. Ghaffari (Tehran University of Medical Sciences)H-Index: 14
view all 11 authors...
Abstract Numerous links exist between inflammation and tumor development. Toll-like receptor 4 (TLR4) expression by tumor cells can be a contributing factor that promotes tumor cell proliferation, survival, migration, and metastasis. In this study, we explored the impact of TLR4 inhibition using TAK-242, a specific inhibitor of TLR4, on the invasion properties of ovarian (A2780CP, 2008C13, SKOV3, and A2780S) and breast (MCF7, SKBR3, MDA-MB-231, and BT-474) cancer cell lines. Six out of eight cel...
3 CitationsSource
#1Alessia Varone (National Research Council)H-Index: 4
#2Stefania Mariggiò (National Research Council)H-Index: 16
Last. Daniela Corda (National Research Council)H-Index: 38
view all 20 authors...
Background Shp1, a tyrosine-phosphatase-1 containing the Src-homology 2 (SH2) domain, is involved in inflammatory and immune reactions, where it regulates diverse signalling pathways, usually by limiting cell responses through dephosphorylation of target molecules. Moreover, Shp1 regulates actin dynamics. One Shp1 target is Src, which controls many cellular functions including actin dynamics. Src has been previously shown to be activated by a signalling cascade initiated by the cytosolic-phospho...
1 CitationsSource
#1Astrid Jullumstrø Feuerherm (NTNU: Norwegian University of Science and Technology)H-Index: 8
#2Edward A. Dennis (UCSD: University of California, San Diego)H-Index: 86
Last. Bent Johansen (NTNU: Norwegian University of Science and Technology)H-Index: 22
view all 3 authors...
Background Cytosolic phospholipase A2 group IVA (cPLA2α)-deficient mice are resistant to collagen-induced arthritis, suggesting that cPLA2α is an important therapeutic target. Here, the anti-inflammatory effects of the AVX001 and AVX002 cPLA2α inhibitors were investigated.
1 CitationsSource
#1Kunlin Wu (Fujian Medical University)H-Index: 4
#2Huihao Zhang (Fujian Medical University)H-Index: 4
Last. Xiangjin Chen (Fujian Medical University)H-Index: 4
view all 9 authors...
5 CitationsSource
#1Zhiqiang LiH-Index: 2
#2Miao QuH-Index: 2
Last. Peng Zhang (HUST: Huazhong University of Science and Technology)H-Index: 10
view all 7 authors...
Abstract Advanced breast cancer is resistant to chemotherapy and its underlying mechanisms are not fully explored. In this work, we identified cytosolic phospholipase A2 alpha (cPLA2α) as a novel target to overcome chemoresistance in breast cancer. We demonstrated the increased transcriptional and translational expression of cPLA2α in breast cancer cells to acute and chronic exposure to doxorubicin. cPLA2α upregulation is also observed in breast cancer patients in response to chemotherapy. Inhib...
7 CitationsSource
#1Hui Fu (Tianjin University of Traditional Chinese Medicine)H-Index: 3
#2Yuchao He (TMUCIH: Tianjin Medical University Cancer Institute and Hospital)H-Index: 3
Last. Hua Guo (TMUCIH: Tianjin Medical University Cancer Institute and Hospital)H-Index: 8
view all 9 authors...
16 CitationsSource
#1Laura M. Snell (UHN: University Health Network)H-Index: 7
#2Tracy L. McGaha (U of T: University of Toronto)H-Index: 26
Last. David G. Brooks (U of T: University of Toronto)H-Index: 6
view all 3 authors...
Type I interferons (IFN-Is) are emerging as key drivers of inflammation and immunosuppression in chronic infection. Control of these infections requires IFN-I signaling; however, prolonged IFN-I signaling can lead to immune dysfunction. IFN-Is are also emerging as double-edged swords in cancer, providing necessary inflammatory signals, while initiating feedback suppression in both immune and cancer cells. Here, we review the proinflammatory and suppressive mechanisms potentiated by IFN-Is during...
63 CitationsSource
9 CitationsSource
#2A. HabichtH-Index: 1
Last. Robert Gniadecki (U of A: University of Alberta)H-Index: 41
view all 6 authors...
Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was investigated in a randomized, double-blind, placebo-controlled, split-design, first-in-man study in patients with mild to moderate psoriasis.The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0.002% to 5.0%. Safety was assessed as local skin reaction adverse events (LSRAE) grades 3-4. The secondary objective...
6 CitationsSource
Cited By1
Ceramide kinase (CerK) is a lipid kinase that converts the proapoptotic ceramide to ceramide 1-phosphate, which has been proposed to have pro-malignant properties and regulate cell responses such as proliferation, migration, and inflammation. We used the parental human breast cancer cell line MDA-MB-231 and two single cell progenies derived from lung and bone metastasis upon injection of the parental cells into immuno-deficient mice. The lung and the bone metastatic cell lines showed a marked up...